The Semaglutide peptide has emerged as a compelling subject in biochemical and physiological research due to its potential ...

In this 2025 availability update, Remote Pharmacy highlights the expanded access to non-branded GLP-1-based weight management ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

Once everyone’s had enough of injections, side effects, and the vast expense of GLP-1 drugs, it could be natural alternatives ...

GLP-1RA use necessitated shifting priorities in nutrition and lifestyle modification among patients with obesity, according ...

Dapiglutide, a novel GLP-1/GLP-2 receptor agonist, was associated with body weight reductions of up to 8.3% at 13 weeks for ...

The Delhi High Court has instructed India's drug regulator to address concerns about the approval process for drugs like ...

Adolescents and young adults are increasingly using GLP-1 receptor agonists for weight management, raising concerns among ...

The PIL seeks a ban on the marketing and distribution of specific GLP-1 receptor agonist (RA) drugs, namely Semaglutide, ...

GLP-1RA use initially lowered delirium risk but eventually heightened delirium risk after 5 years among patients with type 2 diabetes.

The Delhi High Court on Wednesday directed the Central Drugs Standard Control Organisation (CDSCO) to decide, within 3 month ...

China has approved a new weight-loss drug that is poised to rival Novo Nordisk and Eli Lilly's popular GLP-1 treatments, ...